急性エンドセリンA受容体阻害は,慢性心不全の患者で選択的な肺血管拡張を引き起こす
M M Givertz1, W S Colucci, T H LeJemtel
1Cardiomyopathy Program and Cardiovascular Section, Boston University Medical Center, Boston University School of Medicine, Boston, MA 02118, USA.
Circulation
|June 28, 2000
まとめ
エンドセリンA受容体の抗体であるシタクセンタンは,心不全患者の肺動脈の圧力と抵抗を効果的に低下させた. この選択的肺血管拡張は,慢性心不全に次ぐ肺高血圧の治療に潜在的な利点を示唆しています.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 肺動脈高血圧 肺動脈高血圧 肺動脈高血圧 肺動脈高血圧 肺動脈高血圧
背景:
- 心不全におけるエンドセリン-1 (ET-1) の上昇は,肺動脈の圧力と抵抗の増加と相関する.
- エンドセリンA (ET(A)) 受容体は,肺血管収縮と高縮を媒介する.
- 慢性心不全に対する従来の治療法は,肺血管機能不全を完全に対処することができないことが多い.
研究 の 目的:
- 選択的ET(A) 受容体抗体であるシタクセンタンの急性血液動力学的効果を評価する.
- 慢性心不全患者の肺動脈圧および血管抵抗に対するシタクセンタンの影響を評価する.
- シタクセンタンが,この患者集団における血ET-1濃度の上昇を低下させるかどうかを判断する.
主な方法:
- NYHAクラスIII/IV心不全の48人の患者を対象とした多センター,ダブルブラインド,プラセボ対照試験です.
- 患者は,静脈内シタクセンタン (1.5,3.0,6.0 mg/kg) またはプラセボのエスカレートする用量を投与された.
- ヘモダイナミックパラメータは,注射後6時間間の右心経導管で評価されました.
主要な成果:
- シタクセンタンは,肺動脈シストリック圧,肺動脈平均圧,肺血管抵抗を著しく低下させた.
- シタキセンタンを服用すると,右心房圧とプラズマET-1濃度の有意な低下が観察されました.
- 心拍数,平均動脈圧,心指数,全身血管抵抗に対する有意な影響は見つかりませんでした.
結論:
- シタクセンタンによる急性ET(A) 受容体阻害は,中等から重度の心不全の患者で選択的肺血管拡張を誘発した.
- シタキセタン投与は,血ET-1濃度の低下につながった.
- シタキセタンは,慢性心不全に関連した肺高血圧の治療において有望であることが示されています.
関連する概念動画
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:21Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:10Atelectasis II: Pathophysiology
Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...